🇺🇸 FDA
Patent

US 11780845

FGFR inhibitors and methods of use thereof

granted A61PA61P35/00

Quick answer

US patent 11780845 (FGFR inhibitors and methods of use thereof) held by Relay Therapeutics, Inc. expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Relay Therapeutics, Inc.
Grant date
Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61P, A61P35/00